Inflammation, Pterygium
Conditions
Keywords
bevacizumab, pterygium, treatment, elevation
Brief summary
The purpose of this study is to evaluate that intralesional injection of bevacizumab on primary pterygium can reduce the corneal pterygium area, inflammation, redness and other symptoms.
Detailed description
To evaluate the efficacy and safety of intralesional injection of bevacizumab on primary pterygium treatment
Interventions
DRUGIntralesional injection of bevacizumab
single dose of 2 mg of bevacizumab intralesional injection on pterygium Combination of topical antazoline and tetrahydrozoline four times a day
DRUGTopical antihistamine and vasoconstrictor
combination of topical antazoline HCl 0.05% and tetrahydrozoline HCl 0.04%
Sponsors
Khon Kaen University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* primary pterygium
Exclusion criteria
* previous ocular surgery
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| percentage of corneal pterygium area | 3 years | Prior to receive the treatments, patients were asked to evaluate grading of their own symptoms and underwent clinical grading of the elevation and inflammation of the lesions using slit lamp biomicroscopy by an opthalmologist (OE). Digital photographs of each eye with pterygium were obtained for corneal pterygium area analysis \[Sony Mavica digital still camera MVC-FD83, Japan\]. Each patient was randomly assigned into either treatment group or control group using computer-generated random numbers table. Number of patients with adverse events will be recorded. |
Countries
Thailand
Contacts
Primary ContactOlan Suwan-apichon, MD
Outcome results
None listed